The core activity of MPC Therapeutics SA is the development of innovative products that improve the fitness, persistence and performance of cells, particularly T cells, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs). This is achieved through modulation of mitochondrial function, specifically by targeted influence on the mitochondrial pyruvate carrier (MPC) and other key metabolic pathways. The company develops small molecules that modulate mitochondrial function to enhance the therapeutic efficacy of cell therapies.